纳洛酮并尿激酶治疗大面积急性脑梗死的临床疗效观察

目的探讨纳洛酮并小剂量尿激酶治疗大面积急性脑梗死的安全性与有效性。方法选择发病6-72小时的急性脑梗死患者120例,随机分为对照组、尿激酶组和纳洛酮组各40例,全部患者均给予常规治疗,尿激酶组给予尿激酶治疗,纳洛酮组给予纳洛酮和尿激酶治疗,并于治疗前和治疗后14、28天采用BI量表及治疗前和治疗后90天采用mRS量表评价患者神经功能。结果治疗后14、28天尿激酶组的BI评分明显优于对照组（P〈0.05）,纳洛酮组与对照组比较有显著性差异（P〈0.01）,并且明显优于尿激酶组（P〈0.05）;治疗后90天mRS量表评价纳洛酮组、尿激酶组分别与对照组比较有显著性差异（P〈0.01）,且纳洛酮组与尿激酶组比较也有显著性差异（P〈0.01）。结论纳洛酮合并小剂量尿激酶可以有效地改善大面积急性脑梗死患者的神经功能缺损,提高生活能力,改善生活质量,并且安全性较好。

Naioxone and Urokinase in the Treatment of Acute Cerebral Infarction a Iarge Area of Observation

Objective Low dose of naloxone and urokinase in the treatment of acute cerebral infarction in a large area the safety and effectiveness.Methods 6~72 hours of onset of acute cerebral infarction 120 patients,Randomly divided into control group,urokinase group and the naloxone group 40 cases,All patients were given conventional treatment,Urokinase to urokinase in the treatment group,Naloxone group was treated with naloxone and urokinase,And the treatment before and after treatment with BI scale and 14,28 days before treatment and 90 days after treatment of patients with mRS scale evaluation of nerve function.Results 14,28 days after treatment,urokinase group BI scores were significantly better than the control group（P〈0.05）,Naloxone group compared with the control group there were significant differences（P〈0.01）,And significantly better than the UK group（P〈0.05）;MRS 90 days after treatment,Assessing the naloxone group,urokinase group compared with the control group were significantly different（P〈0.01）,And the naloxone group compared with the UK group,there was a significant difference（P〈0.01）.Conclusion Naloxone combined with low dose of urokinase can effectively improve the large area of cerebral infarction in patients with acute neurological impairment,Life skills,Improve the quality of life,And good safety.